Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
SAN JOSE, Calif., May 08, 2018 -- According to the latest report published by Credence Research, Inc. “Hypercalcemia Treatment Market - Growth, Future Prospects and Competitive Analysis, 2018-2026,” the global hypercalcemia treatment market was valued at US$ 9,544.1 Mn in 2017 and expected to reach US$ 23,707.8 Mn by 2026, expanding at a CAGR of 10.7% from 2018 to 2026.
Market Insights
The global hypercalcemia treatment market is projected to reach US$ 23,707.8 Mn by 2026 from US$ 9,544.1 Mn in 2017, growing at a CAGR of 10.7% during the forecast period from 2018 to 2026. Hypercalcemia is a metabolic disorder caused by elevated levels of calcium, with serum calcium levels above 2.6 mmol/L. Hypercalcemia is generally a result of overactive parathyroid glands and may occur in cancer patients, majorly in lung and breast cancer patients. Some other factors contributing development of disorder includes hereditary factors, severe dehydration, medications, and supplements. Patients are prescribed calcium regulating therapeutics.
Based on the drug class, the global hypercalcemia treatment market is segmented into bisphosphonates, calcitonin, glucocorticoids, calcimimetic agents, and denusomab. Bisphosphonates is further sub-segmented into clodronate, etidronate, ibandronate, pamidronate, and zoledronic acid. In 2017, bisphosphonates segment dominated the global hypercalcemia treatment market due to increased preference for treatment of the disease. Other drug classes including glucocorticoids and calcimimetic agents are expected to experience a steady growth during the forecast period. As generics dominates the market, label extension of the drugs for the treatment of more indications further expected to contribute to the growth of the market.
Based on geographical demarcation, North America and Europe collectively contributed over 63% of the global hypercalcemia treatment market share in 2017 with North America in lead. High prevalence of the malignancy-related hypercalcemia and increased awareness of the disease in both the regions are the prime factors for the dominance. Asia Pacific and Latin America hypercalcemia treatment market are projected to witness the fastest growth at a double digit CAGR during the forecast period due to growing healthcare expenditure and increasing awareness related to hypercalcemia.
The global hypercalcemia treatment market is highly fragmented due to the presence of numerous local and international market players. Since most of the therapeutics are generic, several players are manufacturing the drugs and competing in the global market. Further, some of the players are investing in research & development for hypercalcemia to capture the prominent market share. Key players in the market include Amgen, Inc., Bayer Pharma AG, Mylan N.V., Pfizer Inc., Cipla, Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, and Dr. Reddy’s Laboratories Ltd.
Browse Full Report With TOC, Figures And Tables @ http://www.credenceresearch.com/report/hypercalcemia-treatment-market
Related Reports:
Alzheimer’s Therapeutic Market
Osteoarthritis Treatment Market
Listeria Monocytogenes Infections Treatment Market
About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.
Contact:
Name: Chris Smith
Designation: Global Sales Manager
E-mail: [email protected]
Ph: +1-800-361-8290
Connect With US:
Web: Credence Research
Facebook @ https://www.facebook.com/CredenceResearch
Twitter @ https://twitter.com/CredenceResearc
LinkedIn @ https://us.linkedin.com/company/credenceresearch
G+ @ https://plus.google.com/+Credenceresearch
